Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 3
2016 3
2017 1
2018 1
2019 3
2020 2
2022 1
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
25th Annual Computational Neuroscience Meeting: CNS-2016.
Sharpee TO, Destexhe A, Kawato M, Sekulić V, Skinner FK, Wójcik DK, Chintaluri C, Cserpán D, Somogyvári Z, Kim JK, Kilpatrick ZP, Bennett MR, Josić K, Elices I, Arroyo D, Levi R, Rodriguez FB, Varona P, Hwang E, Kim B, Han HB, Kim T, McKenna JT, Brown RE, McCarley RW, Choi JH, Rankin J, Popp PO, Rinzel J, Tabas A, Rupp A, Balaguer-Ballester E, Maturana MI, Grayden DB, Cloherty SL, Kameneva T, Ibbotson MR, Meffin H, Koren V, Lochmann T, Dragoi V, Obermayer K, Psarrou M, Schilstra M, Davey N, Torben-Nielsen B, Steuber V, Ju H, Yu J, Hines ML, Chen L, Yu Y, Kim J, Leahy W, Shlizerman E, Birgiolas J, Gerkin RC, Crook SM, Viriyopase A, Memmesheimer RM, Gielen S, Dabaghian Y, DeVito J, Perotti L, Kim AJ, Fenk LM, Cheng C, Maimon G, Zhao C, Widmer Y, Sprecher S, Senn W, Halnes G, Mäki-Marttunen T, Keller D, Pettersen KH, Andreassen OA, Einevoll GT, Yamada Y, Steyn-Ross ML, Alistair Steyn-Ross D, Mejias JF, Murray JD, Kennedy H, Wang XJ, Kruscha A, Grewe J, Benda J, Lindner B, Badel L, Ohta K, Tsuchimoto Y, Kazama H, Kahng B, Tam ND, Pollonini L, Zouridakis G, Soh J, Kim D, Yoo M, Palmer SE, Culmone V, Bojak I, Ferrario A, Merrison-Hort R, Borisyuk R, Kim CS, Tezuka T, Joo P, Rho YA, Burt… See abstract for full author list ➔ Sharpee TO, et al. BMC Neurosci. 2016 Aug 18;17 Suppl 1(Suppl 1):54. doi: 10.1186/s12868-016-0283-6. BMC Neurosci. 2016. PMID: 27534393 Free PMC article.
Hines, Liang Chen, Yuguo Yu O9 C. elegans interactome: interactive visualization of Caenorhabditis elegans worm neuronal network Jimin Kim, Will Leahy, Eli Shlizerman O10 Is the model any good? Objective criteria for computational neuroscience model selection Justas Birgio …
Hines, Liang Chen, Yuguo Yu O9 C. elegans interactome: interactive visualization of Caenorhabditis elegans worm neuronal network Jimin Kim, …
α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.
Schmitz M, Candelise N, Canaslan S, Altmeppen HC, Matschke J, Glatzel M, Younas N, Zafar S, Hermann P, Zerr I. Schmitz M, et al. Transl Neurodegener. 2023 Mar 14;12(1):12. doi: 10.1186/s40035-023-00342-4. Transl Neurodegener. 2023. PMID: 36915212 Free PMC article. Review.
Even though the specific cellular distribution of aggregated alphaSyn differs in PD and DLB patients, both groups show a significant pathological overlap, raising the discussion of whether PD and DLB are the same or different diseases. Besides clinical investigation, we will …
Even though the specific cellular distribution of aggregated alphaSyn differs in PD and DLB patients, both groups show a significant patholo …
Impact of supplementation with L-citrulline/arginine after liver transplantation in individuals with Urea Cycle Disorders.
Posset R, Garbade SF, Gleich F, Nagamani SCS, Gropman AL, Epp F, Ramdhouni N, Druck AC, Hoffmann GF, Kölker S, Zielonka M; Urea Cycle Disorders Consortium (UCDC) and the European registry and network for Intoxication type Metabolic Diseases (E-IMD) consortia study group. Posset R, et al. Mol Genet Metab. 2024 Mar;141(3):108112. doi: 10.1016/j.ymgme.2023.108112. Epub 2023 Dec 10. Mol Genet Metab. 2024. PMID: 38301530 Free article.
Further prospective analyses in larger samples and even longer observation periods will provide more insight into the usefulness of long-term supplementation with L-citrulline/arginine for individuals with UCDs who have undergone LTx....
Further prospective analyses in larger samples and even longer observation periods will provide more insight into the usefulness of l …
Severity-adjusted evaluation of newborn screening on the metabolic disease course in individuals with cytosolic urea cycle disorders.
Posset R, Kölker S, Gleich F, Okun JG, Gropman AL, Nagamani SCS, Scharre S, Probst J, Walter ME, Hoffmann GF, Garbade SF, Zielonka M; Urea Cycle Disorders Consortium (UCDC) and the European registry and network for Intoxication type Metabolic Diseases (E-IMD) consortia study group. Posset R, et al. Mol Genet Metab. 2020 Dec;131(4):390-397. doi: 10.1016/j.ymgme.2020.10.013. Epub 2020 Nov 7. Mol Genet Metab. 2020. PMID: 33288448 Free PMC article.
NBS enables the attenuation of the initial HAE but does not affect the frequency of subsequent metabolic decompensations in individuals with CTLN1 and ASA. Future long-term studies will need to evaluate the clinical impact of this finding, especially with regard to mortali …
NBS enables the attenuation of the initial HAE but does not affect the frequency of subsequent metabolic decompensations in individuals with …
The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening.
Hartman G, Humphries P, Hughes R, Ho A, Montgomery R, Deshpande A, Mahanta M, Tronnes S, Cowdin S, He X, Liu F, Zhang L, Liu C, Dou D, Li J, Spasic A, Coll R, Marleaux M, Hochheiser IV, Geyer M, Rubin P, Fortney K, Wilhelmsen K. Hartman G, et al. Bioorg Med Chem Lett. 2024 Apr 1;102:129675. doi: 10.1016/j.bmcl.2024.129675. Epub 2024 Feb 28. Bioorg Med Chem Lett. 2024. PMID: 38417632
We anticipate that compound 3 (BAL-0028) and other members of this novel indazole class of neutral inhibitors will demonstrate significantly different physical, biochemical, and biological properties compared to NLRP3 inhibitors previously identified....
We anticipate that compound 3 (BAL-0028) and other members of this novel indazole class of neutral inhibitors will demonstrate signif …
Monitoring high-risk patients: minimally invasive and non-invasive possibilities.
Renner J, Grünewald M, Bein B. Renner J, et al. Best Pract Res Clin Anaesthesiol. 2016 Jun;30(2):201-16. doi: 10.1016/j.bpa.2016.04.006. Epub 2016 May 5. Best Pract Res Clin Anaesthesiol. 2016. PMID: 27396807 Review.
From this point of view, we are very confident that some of these minimally invasive and non-invasive haemodynamic monitoring technologies will become an inherent part of our monitoring armamentarium in the OR and in the intensive care unit (ICU)....
From this point of view, we are very confident that some of these minimally invasive and non-invasive haemodynamic monitoring technologies …
Is freezing in the vaccine cold chain an ongoing issue? A literature review.
Hanson CM, George AM, Sawadogo A, Schreiber B. Hanson CM, et al. Vaccine. 2017 Apr 19;35(17):2127-2133. doi: 10.1016/j.vaccine.2016.09.070. Vaccine. 2017. PMID: 28364920 Free article. Review.
This literature review is an update to one previously published in 2007 (Matthias et al., 2007), analyzing the prevalence of vaccine exposure to temperatures below recommendations throughout various segments of the cold chain. ...It is important to address this issue by ed …
This literature review is an update to one previously published in 2007 (Matthias et al., 2007), analyzing the prevalence of vaccine …
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L. Pinkerton JV, et al. Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3. Menopause. 2024. PMID: 38564691 Clinical Trial.
Primary endpoints are the mean change in frequency and severity of moderate/severe VMS from baseline to weeks 4 and 12. Key secondary endpoints will assess the onset of action and effects on sleep disturbance and menopause-related quality of life. Primary and key secondary …
Primary endpoints are the mean change in frequency and severity of moderate/severe VMS from baseline to weeks 4 and 12. Key secondary endpoi …
Pediatric Safety of Polysorbates in Drug Formulations.
Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmitt G. Kriegel C, et al. Children (Basel). 2019 Dec 20;7(1):1. doi: 10.3390/children7010001. Children (Basel). 2019. PMID: 31877624 Free PMC article.
To determine safe levels of polysorbates for young patients, we have developed the progressive pediatric safety factor (PPSF), an age- and weight-based tool that estimates the amount of parenterally administered polysorbates 20 and 80 in formulations that will avoid excipi …
To determine safe levels of polysorbates for young patients, we have developed the progressive pediatric safety factor (PPSF), an age- and w …
Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.
Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Moseley MA, Thompson JW, Williams LSJ, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald WM, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, Dunlop BW, Millington DS, Rush AJ, Frye MA, Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC). Ahmed AT, et al. J Affect Disord. 2020 Mar 1;264:90-97. doi: 10.1016/j.jad.2019.11.122. Epub 2019 Nov 30. J Affect Disord. 2020. PMID: 32056779 Free PMC article.
20 results